Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.

Saved in:
Bibliographic Details
Title: Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Authors: Sanchez L; Icahn School of Medicine at Mount Sinai, New York, NY., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY., Cheng M; Analysis Group, Inc., Boston, MA., Cherepanov D; Takeda Development Center Americas, Lexington, MA., DerSarkissian M; Analysis Group, Inc., Boston, MA., Huang F; Takeda Development Center Americas, Lexington, MA., Stull DM; Takeda Development Center Americas, Lexington, MA., Dabora J; Takeda Development Center Americas, Lexington, MA., Young M; Takeda Development Center Americas, Lexington, MA., Noga SJ; Takeda Development Center Americas, Lexington, MA., Pi S; Analysis Group, Inc., Boston, MA., Zhang M; Analysis Group, Inc., Boston, MA., Banatwala A; Analysis Group, Inc., Boston, MA., Duh MS; Analysis Group, Inc., Boston, MA., Ailawadhi S; Mayo Clinic, Jacksonville, FL.
Source: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2023 Nov; Vol. 29 (11), pp. 1205-1218. Date of Electronic Publication: 2023 Sep 30.
Publication Type: Journal Article
Journal Info: Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2376-1032
DOI:10.18553/jmcp.2023.23031